Prescribing information (external link)
LEQVIO® (inclisiran) is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:1
in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.
The effect of LEQVIO® on cardiovascular morbidity and mortality has not yet been determined.1
For full safety information, please refer to the LEQVIO® Summary of Product Characteristics (SmPC).
LEQVIO® resources
Explore our growing repository of resources designed to provide useful information on LEQVIO® and other relevant topics for healthcare professionals (HCPs) treating eligible patients with atherosclerotic cardiovascular disease.
LEQVIO®: A practical guide
Your Guide to LEQVIO®
A quick-guide to LEQVIO®, with information on the NICE recommendation and the NHS commercial agreement through to dosing and administration.
LEQVIO dosing and administration: ‘How to’ guide
This resource is designed to give you an overview of LEQVIO® dosing and administration.
LEQVIO® mechanism of action
LEQVIO® acts in the body in a targeted way to increase LDL-C receptor cycling and expression and help lower LDL-C levels in circulation.1
Watch the video below to learn more about the LEQVIO® mechanism of action.
LEQVIO® in secondary care
Watch Dr Sohail Khan (Queen Elizabeth University Hospital Birmingham) discuss how LEQVIO® can be applied in secondary care.
Prescribing information (external link)
Getting started with LEQVIO® in secondary care
Making LEQVIO® routine in secondary care
Please get in touch with us to speak to one of our Novartis representatives
HCP, healthcare professional; LDL-C, low-density lipoprotein cholesterol.
Reference
LEQVIO® Summary of Product Characteristics.
UK | June 2026 | FA-11668936
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
